Derby's Royal Hospital haematology team manages myeloma and lymphoma patients in the East Midlands requiring Bortezomib-based combination regimens. Bortenat 3.5mg provides Derby's oncology pharmacy with a reliable, cost-effective supply of this essential proteasome inhibitor.
The subcutaneous administration route — now standard at Derby and most UK cancer centres — has transformed Bortezomib tolerability, reducing peripheral neuropathy rates from around 24% with IV to under 6% with SC administration while maintaining equivalent anti-myeloma efficacy. Bortenat 3.5mg vials from WHO-GMP certified Indian facilities provide this same treatment at reduced institutional cost.
Visit medshopy.com or WhatsApp +91 82650 41513 for Derby and East Midlands institutional pricing.
The subcutaneous administration route — now standard at Derby and most UK cancer centres — has transformed Bortezomib tolerability, reducing peripheral neuropathy rates from around 24% with IV to under 6% with SC administration while maintaining equivalent anti-myeloma efficacy. Bortenat 3.5mg vials from WHO-GMP certified Indian facilities provide this same treatment at reduced institutional cost.
Visit medshopy.com or WhatsApp +91 82650 41513 for Derby and East Midlands institutional pricing.
